Related Experiment Video
Updated: Aug 7, 2026
10:50
Design and Use of a Low Cost, Automated Morbidostat for Adaptive Evolution of Bacteria Under Antibiotic Drug Selection
Published on: September 27, 2016
Moclobemide: evolution, pharmacodynamic, and pharmacokinetic properties
1Rheinische Kliniken Essen, Department of Psychiatry and Psycotherapy, University of Essen, Essen, Germany. udo.bonnet@uni-essen.de.
CNS Drug Reviews
|September 28, 2002
Summary
Moclobemide, a reversible inhibitor of monoamine-oxidase-A (RIMA), is reviewed for its properties and effects. This article surveys its impact on neurotransmission, the neuroendocrine system, and various central nervous system functions.
Area of Science:
- Pharmacology
- Neuroscience
- Psychiatry
Background:
- Moclobemide is a benzamide compound functioning as a reversible inhibitor of monoamine-oxidase-A (RIMA).
- It has been investigated for treating depressive and anxiety disorders.
Purpose of the Study:
- To review the evolution, pharmacodynamic, and pharmacokinetic properties of moclobemide.
- To survey its effects on neurotransmission, intracellular signaling, and the neuroendocrine system.
- To examine its impact on the tyramine response, animal models of depression, and other central nervous system (CNS) effects.
Main Methods:
- Literature review focusing on moclobemide's properties and effects.
- Survey of studies on neurotransmission and intracellular signal transduction.
- Analysis of data concerning the tyramine pressure response and animal models of depression.
Main Results:
- Moclobemide influences neurotransmission and intracellular signal transduction.
- It affects the neuroendocrine system and the tyramine pressure response.
- The drug exhibits various CNS effects, including anxiolytic and antinociceptive activities, and influences sleep, cognition, and neuroprotection.
Conclusions:
- Moclobemide's pharmacodynamic and pharmacokinetic profile supports its therapeutic potential.
- Further research is warranted to fully elucidate its CNS effects and clinical applications.
Related Concept Videos
01:10Pharmacokinetics: Overview
Pharmacokinetics is a scientific discipline that focuses on the journey of a drug within the body, encompassing four key stages: absorption, distribution, metabolism, and elimination. The first stage, absorption, involves the drug's transfer into the bloodstream. Several factors dictate the extent and speed of this process. For example, the liver often metabolizes oral drugs before they reach systemic circulation, leading to only partial absorption. In contrast, intravenous (IV) administration...
01:16Drug Biotransformation: Overview
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
01:28Drug Biotransformation: Overview
Biotransformation, also known as drug metabolism, is a vital physiological process that chemically alters drugs, facilitating their elimination from the body and terminating their action. This process involves two main phases: phase I and phase II reactions. Phase I reactions, including oxidation, reduction, and hydrolysis, introduce or unmask polar functional groups on the drug molecule, thereby increasing its water solubility. By enhancing water solubility, the drug becomes more hydrophilic...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:14Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship
For drugs producing a quantal response, onset occurs when plasma concentration reaches a minimum effective level (Cmin). The drug's action duration depends on how long the plasma concentration remains above Cmin.Two primary factors influence this duration: dose size and the rate of drug removal from the action site. Both depend on the drug's redistribution to poorly perfused tissues and elimination processes. A larger dose promotes rapid onset and prolongs the effect's duration.Consider a...
01:23Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration
Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s half-life.